NovAliX enters into multi-target intergrated drug discovery collaboration with Teijin Pharma
Strasbourg, France, January 12, 2011 / b3c newswire
NovAliX SAS announced today that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.
Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX will initially use its protein biochemistry expertise in combination with its comprehensive biophysical technology platform. NovAliX will apply its proprietary Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterization of selected small molecule hit structures.
This arrangement represents NovAliX’ first discovery collaboration with Teijin Pharma. Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments. Financial details of the transaction were not disclosed.
Stephan Jenn, President of NovAliX, stated, ”We are confident that this alliance will be very productive and are proud to be associated with Teijin’s technology-driven team. In this collaboration Teijin will have the opportunity to leverage the entire spectrum of our capabilities in biochemistry, biophysics and medicinal chemistry. For NovAliX this integrated collaboration represents a significant milestone as Teijin is the second Japanese pharmaceutical company to partner with us this year. This alliance underlines again the competitive edge of our scientific expertise and biophysical technologies as well as our commitment to serve the Japanese pharmaceutical research market that is strongly driven by science and innovation.”
NovAliX is providing enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing. With its proprietary Graffinity SPR technology, X-ray protein crystallography, native mass spectrometry and chemistry NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams. NovAliX Group, a team of 130 scientists, is located in Strasbourg-Illkirch (France) and Heidelberg (NovAliX’s Graffinity subsidiary in Germany). More info at: www.novalix-pharma.com.
Denis Zeyer, CEO
Bld Sébastien Brant, BP 30170
F-67405 Illkirch CEDEX FRANCE
Phone : +33 368 330 200